Pacira BioSciences (PCRX) Free Cash Flow (2010 - 2026)

Pacira BioSciences' Free Cash Flow history runs 17 years deep, the most recent figure standing at $24.3 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 29.9% year-over-year to $24.3 million in Q1 2026; TTM through Mar 2026 was $126.3 million, a 25.72% decrease from a year earlier, with the FY2025 full-year figure at $136.7 million, down 25.66% from the prior year.
• Free Cash Flow fell to $24.3 million in Q1 2026 per PCRX's latest filing, from $43.5 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $57.0 million in Q3 2025 and bottomed at $1.5 million in Q2 2025.
• The 5-year median for Free Cash Flow is $36.5 million (2022), against an average of $35.3 million.
• Across the five-year window, Free Cash Flow surged 2573.08% in 2022 and sank 96.9% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at $36.5 million in 2022, then retreated by 7.26% to $33.9 million in 2023, then grew by 6.47% to $36.1 million in 2024, then increased by 20.47% to $43.5 million in 2025, then sank by 44.06% to $24.3 million in 2026.
• Per Business Quant, the three latest PCRX Free Cash Flow figures stand at $24.3 million (Q1 2026), $43.5 million (Q4 2025), and $57.0 million (Q3 2025).